[iBET – ITQB Seminar] Innovation in Biologics Manufacturing

iBET – ITQB Seminar

Title: Innovation in Biologics Manufacturing

Speaker: Hitto Kaufmann

Affiliation: Vice President Technology and Development Sanofi Biologics, Germany

Host: Paula M. Alves, Animal Cell Technology Unit

Abstract:

Manufacturing platforms for biologics have a fundamental effect not only on development speed, manufacturing robustness and cost of goods but also on the efficacy and half-life of the drug product. The field is still highly driven by innovation that spans more and more across the different disciplines involved. Convergence of the scientific areas from cell culture and fermentation, to protein sciences, pharmaceutical sciences and engineering will provide the next leap in process excellence. This presentation will discuss how synergies between a diverse biologics portfolio from vaccines to single chain proteins can be leveraged to implement novel technologies across a broad biologics platform.

Short CV:

Hitto Kaufmann is currently Vice President Technology and Development Sanofi Biologics. The corporate division Technology and Development spans across all Sanofi Biologics businesses including vaccines, antibodies, antibody derivatives, glycosylated enzymes, insulins and gene therapeutics. Previously Hitto Kaufmann was heading the Process Sciences at Boehringer Ingelheim in Biberach responsible for drug substance and drug product process development from the interface with discovery to commercial and post-launch process development and characterization. The department also operated clinical supply facilities for GMP drug substance and drug product manufacturing. In various positions Hitto worked with new biological entities as well as biosimilars. Prior to joining Boehringer Ingelheim he worked in research focusing on drug target-discovery in the field of apoptosis. Hitto holds a PhD from the ETH Zurich working with Martin Fussenegger and Jay Bailey and a master degree in biotechnology from the TU Braunschweig and The Scripps Research Institute in San Diego. Hitto is member in several international boards including the ESACT executive committee.